Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL),
To evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs; Total NSAID, include COX-II inhibitors and non-selective NSAIDs; COX-II, cyclooxygenase II inhibitors; MACEs, major adverse cardiac events
